Skip to main content
SpringerLink
Log in

Zafirlukast: another option for asthma therapy

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Adkins JC, Brogden RN. Zafirlukast: a review of its pharmacology and therapeutic potential in the management of asthma. Drugs 1998; Jan; 55(1): 121–44

    Article  PubMed  CAS  Google Scholar 

  2. Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin Ther 1997; 19(4): 675–90

    Article  PubMed  CAS  Google Scholar 

  3. Nathan RA, Hanby LA, Kylstra JW, et al. Zafirlukast improves symptoms of asthma and quality of life in asthmatic patients with moderate airflow obstruction [abstract]. Eur Respir J 1997 Sep; 10 Suppl. 25: 438s

    Google Scholar 

  4. Barnes NC, Black B, Syrett N, et al. Reduction of exacerbations of asthma in multi-national clinical trials with zafirlukast (Accolate™) [abstract]. Allergy 1996; 51 Suppl. 30: 84

    Google Scholar 

  5. Holgate ST, Anderson KD, Rodgers EM. Comparison of Accolate™ (zafirlukast) with sodium cromoglycate in mild to moderate asthmatic patients [abstract]. Allergy 1995; 50 Suppl. 26: 319–20

    Google Scholar 

  6. Nathan RA, Glass M, Snader L. Thirteen weeks of treatment with zafirlukast (Accolate™) or cromolyn sodium (IntalRm) in patients with mild or moderate asthma [abstract]. Asthma 95: Theory to Treatment; 1995 Jul 15; Chicago, 46

    Google Scholar 

  7. Laitinen LA, Naya IP, Binks S, et al. Comparative efficacy of zafirlukast and low dose steroids in asthmatics on prn β2-agonists [abstract]. Eur Respir J 1997 Sep; 10 Suppl. 25: 419s

    Google Scholar 

  8. Laitinen LA, Zetterström O, Holgate ST, et al. Effects of Accolate™ (zafirlukast; 20 mg bd) in permitting reduced therapy with inhaled steroids: a multicenter trial in patients with doses of inhaled steroid optimised between 800 and 2000 mcg per day [abstract]. Allergy 1995; 50 Suppl. 26: 320

    Google Scholar 

  9. Bateman ED, Holgate ST, Binks SM, et al. A multicentre study to assess the steroid-sparing potential of Accolate™ (zafirlukast; 20 mg BD) [abstract]. Allergy 1995; 50 Suppl. 26: 320

    Google Scholar 

  10. Virchow JC, Hassall SM, Summerton L, et al. Improved asthma control over 6 weeks with zafirlukast in patients on high dose inhaled corticosteroids [abstract]. Eur Respir J 1997 Sep; 10 Suppl. 25: 437s

    Google Scholar 

  11. Virchow JCJ, Hassall SM, Summerton L, et al. Zafirlukast (Accolate™) reduces the impact of asthma in patients taking inhaled corticosteroids [abstract]. 16th International Congress of Allergology and Clinical Immunology; 1997 Oct 22–23; Mexico, Suppl. 4, 243

  12. Zeneca Pharmaceuticals. Zafirlukast product monograph. Cheshire, UK, August 1997

  13. Wechsler ME, Garpestad E, Filer SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998 Feb 11; 279: 455–7

    Article  PubMed  CAS  Google Scholar 

  14. Suissa S, Dennis R, Ernst P. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997 Feb 1; 126: 177–83

    PubMed  CAS  Google Scholar 

  15. Klim JB, Brown J, Syrett N, et al. Cost impact of reducing exacerbations of asthma in multi-national clinical trials with zafirlukast [abstract no. P0382]. Eur Respir J 1996; 9 Suppl. 23: 52s

    Google Scholar 

  16. British Asthma Guidelines Coordinating Committee. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997 Feb; 52 Suppl. 1: S1–S21

    Google Scholar 

  17. Highlights of the expert panel report 2: Guidelines for the diagnosis and management of asthma. 1997: ii–viii, 1–50. National Institutes of Health National Heart, Lung, and Blood Institute (NHLBI) Symposium at the 1997 Annual Meeting of the American Academy of Allergy, Asthma, and Immunology, NIH Publication No 97-4051A, May 1997

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zafirlukast: another option for asthma therapy. Drugs Ther. Perspect 11, 1–4 (1998). https://doi.org/10.2165/00042310-199811070-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199811070-00001

Keywords

Search

Navigation